Image

United States Hypophosphatasia Molecular Research Center

Recruiting
1 - 120 years of age
Both
Phase N/A

Powered by AI

Overview

This study is being done to determine if cryptic alterations exist within or near to the ALPL gene in patients with a clinical diagnosis of hypophosphatasia, but without identifiable alteration on commercial testing. Additionally, the study aims to characterize functional effects of certain variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia.

Description

Primary Study Objectives:

Determine if cryptic alterations exist within or near to the ALPL gene in patients with clinical diagnosis of hypophosphatasia, but without identifiable pathogenic or likely pathogenic variant on commercial testing.

Secondary Study Objective(s):

Characterize functional effects of variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia

Further characterize the differential diagnosis of hypophosphatasemia in patients with skeletal disease

Eligibility

Inclusion Criteria:

Aim 1-

  1. Diagnosis of Hypophosphatasia based on clinical features that include
    • History consistent with diagnosis of hypophosphatasia AND
    • Physical examination findings consistent with a diagnosis of hypophosphatasia AND
    • Presence of low serum alkaline phosphatase level for age and sex AND
    • Elevation of at least one natural substrate of alkaline phosphatase
  2. Lack of detection of a variant on molecular analysis of the ALPL gene. When possible,

    first degree relatives (parents, siblings, or child) will be included for the sole purpose of trio testing. No additional information will be collected on first degree relatives.

Aim 2-

  1. Missense variant in ALPL which is interpreted as a variant of uncertain significance by the American College of Medical Genetics Guidelines for Variant Interpretation
  2. Variant has been interpreted as pathogenic, likely pathogenic, likely benign, or benign using ex-US interpretation guidelines

Exclusion Criteria:

Aim 1-

  1. History and physical examination incompatible with a diagnosis of hypophosphatasia OR
  2. Absence of hypophosphatasemia as measured by age and sex-matched control OR
  3. Absence of at least one elevated natural substrate of alkaline phosphatase OR
  4. Alternate diagnosis which could overlap with signs and symptoms of hypophosphatasia

Aim 2-

  1. Inability to express variant in plasmid for residual enzyme and co-transfection analyses

Study details

Hypophosphatasia

NCT05062629

Children's Mercy Hospital Kansas City

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.